Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia

Blood

Volumn 102, Issue 13, 2003, Pages 4541-4546

  Holleman, Amy ^b   Den Boer, Monique L ^a   Kazemier, Karin M ^b   Janka Schaub, Gritta E ^b   Pieters, Rob ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CASPASE 3; DAUNORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARONAL; PHOSPHATIDYLSERINE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL;

EID: 0344305439     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3612     Document Type: Article

References (49)

1. Greaves M. Childhood leukaemia. BMJ. 2002;324:283-287.
2. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399-403.
3. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998;92:259-266.
4. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998;12:1344-1348.
5. Sen S, D'Incalci M. Apoptosis: biochemical events and relevance to cancer chemotherapy. FEBS Lett. 1992;307:122-127.
6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukaemic cells. Nat Med. 1996;2:574-577.
7. Eischen CM, Kottke TJ, Martins LM, et al. Comparison in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997;90:935-943.
8. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845-1853.
9. Solary E, Droin N, Bettaieb A, et al. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia. 2000;14:1833-1849.
10. Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene. 1998;17:3207-3212.
11. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
12. Castedo M, Macho A, Zamzami N, et al. Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol. 1995;25:3277-3284.
13. Li P, Nijhawan D, Budhihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489.
14. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell. 1998;1:949-957.
15. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
16. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028-1042.
17. Raisova M, Bektas M, Wieder T, et al. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett. 2000;473:27-32.
18. Kojima H, Endo K, Moriyama H, et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 1998;273:16647-16650.
19. Wolf BB, Schuler M, Li W, et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem. 2001;276:34244-34251.
20. Jia L, Srinivasula SM, Liu F, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood. 2001;98:414-421.
21. Soengas MS. Inactivation of the apoptosis effector apaf-1 in malignant melanoma. Nature. 2001;409:207-211.
22. Martinez-Lorenzo MJ, Gamen S, Etxeberria J, et al. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells. Int J Cancer. 1998;75:473-481.
23. Eggert A, Grosser MA, Suzan TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001;61:1314-1319.
24. Meinhardt G, Roth J, Totok G, Auner H, Emmerich B, Hass R. Signalling defect in the activation of caspase-3 and PKCδ in human leukemia cells is associated with resistance to apoptosis. Exp Cell Res. 1999;247:534-542.
25. Pieters R, Loonen AH, Huismans OR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76:2327-2336.
26. Pieters R, Huismans DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett. 1988;41:323-332.
27. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol. 1988;4:155-181.
28. Ravandi F, Kantarjian HM, Talpaz M, et al. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001;91:1964-1972.
29. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92:3090-3097.
30. Faderl S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999;5:4041-4047.
31. Castedo M, Hirsch T, Susin SA, et al. Sequential acquisition of mitochondrial alterations during early lymphocyte apoptosis. J Immunol. 1996;157:512-521.
32. Backway KL, McCulloch EA, Chow S, Hedley DW. Relationship between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res. 1997;75:2446-2452.
33. Denecker G, Dooms H, Van Loo G, et al. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett. 2000;465:47-52.
34. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
35. Svingen PA, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspase-2, -3, -7, -8, -9 as potential prognostic markers in acute leukemia. Blood. 2000;96:3922-3931.
36. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1855-1859.
37. Itoh M, Kitano T, Watanabe M. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukaemia. Clin Cancer Res. 2003;9:415-423.
38. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11:1833-1841.
39. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953.
40. Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996;87:1140-1146.
41. Uckun FM, Yang Z, Sather H, et al. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1997;89:3769-3777.
42. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphoblastic leukemia. Blood. 1997;93:2671-2678.
43. Prokop A, Wieder T, Sturm I, et al. Relapse in childhood acute lymphoblastic leukaemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000;14:1606-1613.
44. Zhou M, Gu L, Abshire TC. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia. 2000:61-67.
45. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-3997.
46. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene. 1998;16:1899-1902.
47. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 1998;92:3410-3415.
48. Kasimir-Bauer S, Beelen D, Flasshove M, et al. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol. 2002;30:1302-1308.
49. Chant ID, Rose PE, Morris AG. Susceptibility of AML cells to in vitro apoptosis correlates with heat shock protein 70 (hsp 70) expression. Br J Haematol. 1996;93:898-902.